Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

By Andrew Silver SHANGHAI, April 22 (Reuters) - Pfizer’s GLP-1 weight management treatment Xianweiying is available for ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

The healthcare giant has been investing heavily in its future growth.

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...

Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, ...

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Although it's not generating tons of money from its COVID vaccine and pill anymore, the business is still doing well. There ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

A $500,000 retirement portfolio spread across five income-focused stocks can generate a blended yield of roughly 7.4%, ...